Dr. Carlos Dujovne MD
Affiliate Professor of Medicine, OREGON HEALTH & SCIENCE UNIVERSITY - CC
Member of the Healthcare Council
Council Member Biography
Carlos Dujovne is an Affiliate Professor of Medicine, CV Division, Director, Clinical Cardiovascular-Metabolic Risk Treatment, and Prevention Programs at Oregon Health and Science University, Portland, OR. He is Board Certified/qualified, Internist, Gastroenterologist, Clinical Pharmacologist and Certified Clinical Lipidologist. Formerly, Dr. Dujovne was a Professor of Medicine & Pharmacology, Director, Clinical Pharmacology's Lipid Arteriosclerosis Prevention &Treatment Clinic, Department of Medicine and Pharmacology, University of KS Chmn, KS Foundation for Clinical Pharmacology and Therapeutics. He conducted clinical R&D trials for all lipid-regulating, anti-obesity drugs and food/dietary supplements. He has authored over 200 scientific articles and 16 book chapters. Dr. Dujovne is the founding member, Board of Directors, Natl. Lipid Assn, member AHA, ASPET and Diabetes. He is the Principal Investigator, Phases I-IV Clinical Trials for R & D of all marketed lipids regulating and anti-obesity drugs. He has been a Consultant to FDA and AdvisoryBoards of many Pharma and Biotech Companies. (This is me - Update Profile)
Employment History
- 2008 - Unspecified
- Affiliate Professor of Medicine, OREGON HEALTH & SCIENCE UNIVERSITY - CC
- 1970 - 1998
- Professor of Medicine & Pharmacology, UNIVERSITY OF KANSAS
GLG NewsSM Analyses by Carlos Dujovne
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
November 13, 2008
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com
1:Crestor is the most potent statin in the market,yet is 3d in sales behind Zocor and Lipitor.2:The efficacy supriority together with its capacity to lower CRP levels led to the highest rate of ASCVD prevention in the shortest period of time evr documented in statin trials.3:The trial in near 18,000 patients with otherwise lower risk of ASCVD offered $0% reduction y many ascvd endpoints.4:There were no statistical differences in side effect compared to placebo.5:The dosage was 20 mg /day (an intermediate dose below the approved max dose of 40 mg/day
-
September 29, 2008
Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
This article is not news for clinical researchers like myself that have performed hundreds of clinical trials in collaboration with the Pharmaceutical Industry. Some of the most common reasons for that are: A)Negative studies are difficult to get published.B)Negative results for the dug of the sponsor company are of potentially damaging financial for the sponsor.C)There is no FDA regulation that prohibits a sponsor to deny access to data and freedom of publication to Investigators of the trial not employed by them. Some of the possible solutions for these problems are:A)Complete freedom of access and publication of data by investigators.B)Sponsors of studies be obligated to submit result regardless of outcome,to FDA.C)Studies shall be easily searchable in a Google style manner at FDA files,by naming a company ,a drug ,a condition,etc,etc.
-
June 23, 2008
After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 | newsroom.lilly.com
More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.
-
February 19, 2008
China Plant Played Role | online.wsj.com
1:Most of our legislators are forcefully endorsing generic drug usage and importing cheaper drugs.2:As a physician specialist in Clinical Pharmacologist I am fully aware or the safety and efficacy pitfalls of poorly manufactured drugs and have done clinical research documenting the risks of patients treated with them.3:For that reason I strongly advised my patients to buy branded drugs by reputable Pharmaceutical Companies who have much to loose if found to manufacture poorly made drugs.
-
January 23, 2008
No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com
One, twenty years ago I was the chairman of the government affairs committee of the American Society for Clinical Pharmacology and Therapeutics; under that role my committee was successful lobbying for approval new investigational drugs for possible treatment of AIDS. We were successful in getting the FDA to approve the testing of those drugs to dying AIDS patients. Such approval led to the discovery and successful drugs we have available today for the treatment of AIDS. Two, This scenario can be easily applied to patients that are dying from any other incurable diseases where drugs that have the potential for serious toxicity cannot be ethically tested in human volunteers or patients with the same disease but not yet at a terminal stage.
GLG Study Groups with Carlos Dujovne(?)
| Study Group Name | No. Members |
|---|---|
| General Cardiologists (US) | 1362 |
| Physicians who Treat Hypertension (US) | 949 |
| Generic Drug Economic Experts | 890 |
| Gastroenterologists (US) | 801 |
| Physicians who Treat Diabetes (US) | 638 |
GLG Live Meetings with Carlos Dujovne(?)
Carlos Dujovne has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.